

Resistant Wet AMD Rescue with Brolucizumab Therapy

José Israel Araújo Ponte, Rodrigo Dantas Nagashima, Lyna Pessoa Jucá Machado, Gabriela Martins de Sá, José Augusto Conrado, Mariana Melo Gontijo, João Augusto Lima Bisneto, Antônio Murillo Fernandes Sales



CLDO **CCO**
CENTRO DE LASER E
DIAGNÓSE OCULAR Centro Cearense de Oftalmologia
HOSPITAL DE OLHOS




Clinical Case



- 72-year-old women
 - No medical history
- Subtle bilateral (but not simultaneous) vision loss in late 2019
 - BCVA: 20/40 Both Eyes
 - IOP and Biomicroscopy: unremarkable
 - Retinography/Fundus Examination/OCT
 - Wet AMD
 - Intraretinal and subretinal Fluid



- Prompt Treatment (Aflibercept)
 - Right Eye: Full Anatomic Response and 20/40 up to present date
 - **Left Eye: Persisted with small amount of subretinal fluid** until early 2022 despite treatment
 - Vision started decreasing down to 20/400
- Switched to Ranibizumab (5 monthly doses)
 - No Success
- Ranibizumab every 2 weeks (4 doses)
 - No Success



- October/2022
 - Brolucizumab 01 dose
 - Full Anatomic Resolution after 01 month
 - Vision was maintained
- November/2022
 - Second Brolucizumab dose
 - Maintained Vision and Anatomic response



Discussion

- Post-Hoc Analysis (HAWK & HARRIER)
 - Brolucizumab injections side effect
 - Rare, but severe, occlusive retinal vasculitis
- Not all patients are responsive to any Anti-VEGF drug
- Anti-VEGF sensitivity may decrease in some cases
- Although still risks should be considered carefully, Brolucizumab may present as an important alternative for those eyes preventing further vision loss